MicroPort India enters Indian market with Drug Eluting Stent, Coronary Stent India
With its products currently approved for use in over 80 countries worldwide, MicroPortŽ Scientific is contributing to a better world through its life-saving medical therapies and quality-improving care devices being used in patients every 15 seconds. MicroPortScientific Corporation http://www.microportindia.com/ ("MPSC") today announced the commencement of its Indian operations. The Indian arm MicroPort Scientific India Pvt. Ltd., a wholly owned subsidiary of MPSC, is aimed to serve the Indian patients with high-quality and yet affordable medical solutions to save, reshape and improve their quality of their life. "India has the third largest coronary angioplasties cases in the world, and the market has been experiencing rapid growth in recent years due to better access lead by Indian government’s initiative of providing universal health coverage. The
establishment of the Indian subsidiary marks another solid step forward in strengthening the global presence of MPSC," said Jonathan Chen, Senior Vice President of International Operations and Investor Relations. About MicroPort India MicroPort Scientific Corporation, http://www.microportindia.com/ founded in 1998 and headquartered in Shanghai, China, has become a premier medical solution provider covering 10 major medical disciplines including interventional cardiology, orthopedics, endovascular, neurovasular, electrophysiology, diabetes and endocrine management, surgical management and others. With its products currently approved for use in over 5,000 hospitals in 80 countries worldwide.